☆ 4.5 Article

Efficacy of Dupilumab in Children 6 Months to 11 Years Old With Atopic Dermatitis: A Retrospective Real-World Study in China

DERMATITIS (2023)

Related references

Note: Only part of the references are listed.

Article Dermatology

A New Era with the Development of Cytokine-Based Therapy for Pruritus

Rintaro Shibuya et al.

Summary: Pruritus, a common dermatological condition, can significantly impact quality of life. Traditional antipruritic drugs may be ineffective, but recent advancements in molecularly targeted drugs have shown promising results in improving itching without the need for steroids. Understanding the cytokine-mediated mechanism of pruritus is crucial for guiding better therapies.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022)

Add to Collection

Article Dermatology

The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study

Y. Zhao et al.

Summary: In adult Chinese patients with moderate-to-severe AD, Dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favorable safety profile.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series

J. Da et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Amy S Paller et al.

LANCET (2022)

Add to Collection

Article Pediatrics

Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

Maddalena Napolitano et al.

Summary: This study evaluated the effectiveness and safety of dupilumab in the treatment of children aged 6-11 years with atopic dermatitis. The results showed that dupilumab treatment significantly improved disease severity, itching, sleep, and quality of life.

PEDIATRIC DRUGS (2022)

Add to Collection

Article Dermatology

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

A. S. Paller et al.

Summary: The study evaluated the pharmacokinetics, safety, and efficacy of single-dose dupilumab in children with severe AD aged 6 months to 6 years. The results showed generally good tolerability and substantial reduction in clinical signs/symptoms of AD, with slightly better responses in older children.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Allergy

EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis

Ioana Agache et al.

Summary: Atopic dermatitis imposes a significant burden on patients, families and healthcare systems. Management is difficult and there are still many issues that require further clarification.

ALLERGY (2021)

Add to Collection

Article Dermatology

Dupilumab for children and adolescents with atopic dermatitis: An Asian perspective

Shi Yun Chia et al.

Summary: This study retrospectively analyzed the efficacy and safety of dupilumab in Asian children and adolescents with moderate-to-severe AD. The results showed that dupilumab is an effective and safe treatment option for these patients.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Article Pediatrics

Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

Amy S. Paller et al.

Summary: This study assessed laboratory outcomes in children aged 6-11 years with severe atopic dermatitis treated with dupilumab. The results showed no clinically meaningful adverse changes in routine laboratory parameters, indicating that routine laboratory monitoring may not be necessary for this age group when treated with dupilumab for severe AD.

PEDIATRIC DRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data

Pavel Kovalenko et al.

Summary: Population pharmacokinetic analysis of adolescents and children with atopic dermatitis revealed significant covariates including weight, albumin, body mass index, and Eczema Area and Severity Index score. While absorption rate and clearance decreased somewhat with age, no additional dose adjustment beyond weight adjustment was necessary. The model adequately described the pharmacokinetics of dupilumab in the pediatric populations.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)

Add to Collection

Review Allergy

Mechanisms of Dupilumab

Hani Harb et al.

CLINICAL AND EXPERIMENTAL ALLERGY (2020)

Add to Collection

Article Dermatology

Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension

M. J. Cork et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Letter Allergy

EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers

Daphne S. Bakker et al.

ALLERGY (2020)

Add to Collection

Article Dermatology

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Amy S. Paller et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Review Dermatology

Counting the Burden: Atopic Dermatitis and Health-related Quality of Life

Faraz Ali et al.

ACTA DERMATO-VENEREOLOGICA (2020)

Add to Collection

Article Dermatology

Impact of Atopic Dermatitis in Adolescents and their Parents: A French Study

Khaled Ezzedine et al.

ACTA DERMATO-VENEREOLOGICA (2020)

Add to Collection

Letter Dermatology

Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study

H. Uchida et al.

BRITISH JOURNAL OF DERMATOLOGY (2019)

Add to Collection

Article Dermatology

Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis

R. Chopra et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Prevalence of Atopic Dermatitis in Chinese Children aged 1-7 ys

Yifeng Guo et al.

SCIENTIFIC REPORTS (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.